Boston Scientific Corp at Truist Securities Life Sciences Summit Transcript
Great. Hi, everyone. I cover the Medtech space here at True Securities with my team, David Rescott and Sam Brodovsky. We appreciate you joining us this call today. Before we begin, I need to read the following disclaimer. This call is arranged by Truist Securities research for use by institutional investors and issuer clients as defined by FINRA. If you're not an institutional investor or issuer, please disconnect at this time, For required disclosures, please see our website at truistsecurities.com or our equity research library.
On today's call, we have the Investor Relations team from Boston Scientific, including Vice President Susie Lisa and Director Lauren Tengler. I'll start out the call, but if anyone on the line has any questions for management, please e-mail them to me at Kaila, K-A-I-L-A, dot Krum, K-R-U-M, at Truist, T-R-U-I-S-T, dot com, and I'll do my best to get those in.
So Susie, Lauren, thanks so much for joining us today, and sorry about the long-winded intro, but it's great to see you both
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |